Xilio Development Financials

XLO Stock

USD 0.54 0.01 1.55%

Based on the key indicators related to Xilio Development's liquidity, profitability, solvency, and operating efficiency, Xilio Development is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Xilio Development's Cash is very stable compared to the past year. As of the 10th of February 2026, Non Current Assets Total is likely to grow to about 11.3 M, while Other Current Liabilities is likely to drop about 10.5 M.

Covid

Interest Hikes

Xilio Development Balance Sheet Chart

At this time, Xilio Development's Cash is very stable compared to the past year. As of the 10th of February 2026, Non Current Assets Total is likely to grow to about 11.3 M, while Other Current Liabilities is likely to drop about 10.5 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Key indicators impacting Xilio Development's financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Current Ratio

2.41

2.54

Notably Down

Slightly volatile

Investors should never underestimate Xilio Development's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to research Xilio Development's cash flow, debt, and profitability to make informed and accurate decisions about investing in Xilio Development.

Net Income

(55.04 Million)

Build AI portfolio with Xilio Stock

Understanding current and past Xilio Development Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Xilio Development's financial statements are interrelated, with each one affecting the others. For example, an increase in Xilio Development's assets may result in an increase in income on the income statement.

Xilio Development Stock Summary

Xilio Development competes with PDS Biotechnology, Actinium Pharmaceuticals, Tempest Therapeutics, OnKure Therapeutics, and Kezar Life. Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. Xilio Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	US98422T1007
Business Address	828 Winter Street,
Sector	Biotechnology
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	xiliotx.com
Phone	857 524 2466
Currency	USD - US Dollar

Xilio Development Key Financial Ratios

	Return On Equity	-9.08
	Profit Margin	(1.84) %
	Operating Margin	(0.10) %
	Price To Sales	1.15 X
	Revenue	6.34 M

More Fundamentals

Xilio Development Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	221.6M	139.2M	60.9M	71.1M	81.7M	108.5M
Other Current Liab	8.8M	10.4M	11.6M	10.0M	11.5M	10.5M
Net Debt	(177.3M)	(100.4M)	(33.2M)	(47.1M)	(42.4M)	(44.6M)
Retained Earnings	(160.9M)	(249.1M)	(325.5M)	(383.8M)	(345.4M)	(328.1M)
Accounts Payable	3.1M	3.1M	1.1M	2.6M	2.3M	2.4M
Cash	198.1M	120.4M	44.7M	55.3M	63.6M	89.2M
Other Current Assets	4.5M	4.1M	3.4M	4.9M	5.7M	3.8M
Total Liab	36.2M	33.5M	24.1M	53.5M	61.5M	39.1M
Net Invested Capital	195.1M	115.5M	40.1M	17.6M	20.2M	19.2M
Total Current Assets	202.5M	124.5M	48.1M	60.2M	69.3M	93.0M
Net Working Capital	189.7M	103.4M	32.2M	33.0M	29.7M	53.7M
Short Term Debt	883K	7.6M	3.3M	1.2M	1.1M	1.0M

Xilio Development Key Income Statement Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	756K	927K	127.8K	100K	90K	85.5K
Gross Profit	(1.5M)	(1.8M)	(1.9M)	6.3M	7.3M	7.7M
Operating Income	(75.0M)	(89.1M)	(79.1M)	(60.6M)	(54.5M)	(57.2M)
Ebit	(75.0M)	(89.1M)	(79.1M)	(59.6M)	(53.7M)	(56.4M)
Research Development	51.2M	59.2M	52.1M	41.2M	47.4M	48.0M
Ebitda	(73.5M)	(87.3M)	(77.2M)	(58.0M)	(52.2M)	(54.8M)
Cost Of Revenue	1.5M	1.8M	1.9M	1.6M	1.9M	1.5M
Income Before Tax	(75.8M)	(88.2M)	(76.4M)	(58.2M)	(52.4M)	(55.0M)
Net Income	(74.3M)	(87.3M)	(76.4M)	(58.2M)	(52.4M)	(55.0M)

Xilio Development Key Cash Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Investments	(1.1M)	(1.9M)	(995K)	(36K)	(41.4K)	(43.5K)
Change In Cash	178.8M	(77.7M)	(75.7M)	10.8M	9.7M	6.6M
Net Borrowings	(25K)	(85K)	(6.8M)	(3.4M)	(3.0M)	(2.9M)
Free Cash Flow	(81.9M)	(77.6M)	(69.1M)	(18.4M)	(16.6M)	(17.4M)
Depreciation	1.5M	1.8M	1.9M	1.6M	1.9M	1.5M
Other Non Cash Items	173K	224K	160K	3K	2.7K	2.6K
Capital Expenditures	1.1M	1.9M	486K	36K	32.4K	30.8K
Net Income	(75.8M)	(88.2M)	(76.4M)	(58.2M)	(52.4M)	(55.0M)
End Period Cash Flow	199.6M	121.9M	44.7M	57.1M	65.6M	90.4M

Xilio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Xilio Development's current stock value. Our valuation model uses many indicators to compare Xilio Development value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xilio Development competition to find correlations between indicators driving Xilio Development's intrinsic value. More Info.

Xilio Development is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Xilio Development's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Xilio Development's earnings, one of the primary drivers of an investment's value.

Most indicators from Xilio Development's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xilio Development current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xilio Development. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.As of the 10th of February 2026, Selling General Administrative is likely to drop to about 22.2 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 5.8 M

	2023	2024	2025	2026 (projected)
Total Operating Expenses	79.1M	66.9M	77.0M	70.1M
Cost Of Revenue	1.9M	1.6M	1.9M	1.5M

Total Operating Expenses Cost Of Revenue

Xilio Development fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.09	0.3	0.22	0.9	0.59	0.75	0.48	-0.98	-0.32	0.04	1.0	0.68	-0.88	0.85	-0.16	1.0	-0.48	0.08	0.29	0.57	0.55	0.23	0.95	0.2	1.0
Short Long Term Debt Total	0.09		-0.44	-0.65	0.36	-0.65	-0.55	0.56	-0.1	0.8	0.5	0.11	0.51	-0.44	0.23	0.74	0.11	0.42	-0.12	0.74	-0.73	-0.7	-0.66	-0.06	-0.68	0.09
Other Current Liab	0.3	-0.44		0.91	0.01	0.78	0.63	0.44	-0.24	-0.82	0.3	0.27	0.37	-0.18	0.16	-0.82	0.27	-0.98	-0.14	0.17	0.59	0.77	0.74	0.38	0.74	0.28
Total Current Liabilities	0.22	-0.65	0.91		-0.1	0.8	0.64	0.13	-0.18	-0.88	0.22	0.2	0.1	-0.01	0.03	-0.87	0.2	-0.88	0.12	-0.12	0.76	0.83	0.92	0.31	0.73	0.21
Total Stockholder Equity	0.9	0.36	0.01	-0.1		0.28	0.5	0.55	-0.94	0.0	0.0	0.91	0.74	-0.9	0.85	0.16	0.91	-0.21	0.03	0.47	0.3	0.29	-0.11	0.88	-0.08	0.9
Other Liab	0.59	-0.65	0.78	0.8	0.28		0.96	0.11	-0.55	-0.95	-0.21	0.57	0.19	-0.34	0.31	-0.87	0.57	-0.86	-0.12	-0.22	0.91	0.97	0.68	0.69	0.67	0.59
Net Tangible Assets	0.75	-0.55	0.63	0.64	0.5	0.96		0.14	-0.73	-0.84	-0.28	0.74	0.3	-0.49	0.52	-0.7	0.74	-0.76	-0.04	-0.16	0.91	0.94	0.57	0.84	0.61	0.76
Property Plant And Equipment Net	0.48	0.56	0.44	0.13	0.55	0.11	0.14		-0.48	0.03	0.62	0.47	0.95	-0.69	0.55	0.03	0.47	-0.48	-0.22	0.94	-0.1	0.1	-0.04	0.45	0.04	0.46
Net Debt	-0.98	-0.1	-0.24	-0.18	-0.94	-0.55	-0.73	-0.48		0.29	0.0	-0.98	-0.69	0.87	-0.87	0.11	-0.98	0.44	-0.12	-0.31	-0.57	-0.54	-0.19	-0.97	-0.17	-0.98
Retained Earnings	-0.32	0.8	-0.82	-0.88	0.0	-0.95	-0.84	0.03	0.29		0.2	-0.3	0.0	0.08	-0.06	0.95	-0.3	0.85	0.1	0.32	-0.86	-0.94	-0.75	-0.46	-0.73	-0.32
Accounts Payable	0.04	0.5	0.3	0.22	0.0	-0.21	-0.28	0.62	0.0	0.2		0.02	0.52	-0.18	0.15	0.15	0.02	-0.23	0.3	0.68	-0.27	-0.21	0.25	-0.13	-0.02	0.02
Cash	1.0	0.11	0.27	0.2	0.91	0.57	0.74	0.47	-0.98	-0.3	0.02		0.68	-0.88	0.85	-0.14	1.0	-0.45	0.08	0.28	0.56	0.53	0.2	0.95	0.18	1.0
Non Current Assets Total	0.68	0.51	0.37	0.1	0.74	0.19	0.3	0.95	-0.69	0.0	0.52	0.68		-0.79	0.78	0.09	0.68	-0.47	-0.05	0.88	0.04	0.18	0.0	0.63	0.13	0.67
Non Currrent Assets Other	-0.88	-0.44	-0.18	-0.01	-0.9	-0.34	-0.49	-0.69	0.87	0.08	-0.18	-0.88	-0.79		-0.7	0.01	-0.88	0.35	0.19	-0.56	-0.23	-0.29	0.1	-0.84	0.17	-0.88
Other Assets	0.85	0.23	0.16	0.03	0.85	0.31	0.52	0.55	-0.87	-0.06	0.15	0.85	0.78	-0.7		0.18	0.85	-0.32	0.29	0.46	0.32	0.3	0.11	0.77	0.31	0.85
Long Term Debt	-0.16	0.74	-0.82	-0.87	0.16	-0.87	-0.7	0.03	0.11	0.95	0.15	-0.14	0.09	0.01	0.18		-0.14	0.81	0.27	0.32	-0.74	-0.85	-0.69	-0.31	-0.58	-0.16
Cash And Short Term Investments	1.0	0.11	0.27	0.2	0.91	0.57	0.74	0.47	-0.98	-0.3	0.02	1.0	0.68	-0.88	0.85	-0.14		-0.45	0.08	0.28	0.56	0.53	0.2	0.95	0.18	1.0
Common Stock Shares Outstanding	-0.48	0.42	-0.98	-0.88	-0.21	-0.86	-0.76	-0.48	0.44	0.85	-0.23	-0.45	-0.47	0.35	-0.32	0.81	-0.45		0.12	-0.2	-0.69	-0.85	-0.72	-0.57	-0.72	-0.47
Non Current Liabilities Total	0.08	-0.12	-0.14	0.12	0.03	-0.12	-0.04	-0.22	-0.12	0.1	0.3	0.08	-0.05	0.19	0.29	0.27	0.08	0.12		-0.12	0.21	-0.02	0.46	-0.05	0.22	0.09
Capital Lease Obligations	0.29	0.74	0.17	-0.12	0.47	-0.22	-0.16	0.94	-0.31	0.32	0.68	0.28	0.88	-0.56	0.46	0.32	0.28	-0.2	-0.12		-0.37	-0.2	-0.24	0.24	-0.16	0.27
Other Current Assets	0.57	-0.73	0.59	0.76	0.3	0.91	0.91	-0.1	-0.57	-0.86	-0.27	0.56	0.04	-0.23	0.32	-0.74	0.56	-0.69	0.21	-0.37		0.95	0.77	0.67	0.63	0.58
Other Stockholder Equity	0.55	-0.7	0.77	0.83	0.29	0.97	0.94	0.1	-0.54	-0.94	-0.21	0.53	0.18	-0.29	0.3	-0.85	0.53	-0.85	-0.02	-0.2	0.95		0.73	0.69	0.69	0.55
Total Liab	0.23	-0.66	0.74	0.92	-0.11	0.68	0.57	-0.04	-0.19	-0.75	0.25	0.2	0.0	0.1	0.11	-0.69	0.2	-0.72	0.46	-0.24	0.77	0.73		0.24	0.74	0.22
Net Invested Capital	0.95	-0.06	0.38	0.31	0.88	0.69	0.84	0.45	-0.97	-0.46	-0.13	0.95	0.63	-0.84	0.77	-0.31	0.95	-0.57	-0.05	0.24	0.67	0.69	0.24		0.26	0.95
Property Plant And Equipment Gross	0.2	-0.68	0.74	0.73	-0.08	0.67	0.61	0.04	-0.17	-0.73	-0.02	0.18	0.13	0.17	0.31	-0.58	0.18	-0.72	0.22	-0.16	0.63	0.69	0.74	0.26		0.19
Total Current Assets	1.0	0.09	0.28	0.21	0.9	0.59	0.76	0.46	-0.98	-0.32	0.02	1.0	0.67	-0.88	0.85	-0.16	1.0	-0.47	0.09	0.27	0.58	0.55	0.22	0.95	0.19

Click cells to compare fundamentals

Xilio Development Account Relationship Matchups

Xilio Development fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	221.6M	139.2M	60.9M	71.1M	81.7M	108.5M
Other Current Liab	8.8M	10.4M	11.6M	10.0M	11.5M	10.5M
Net Debt	(177.3M)	(100.4M)	(33.2M)	(47.1M)	(42.4M)	(44.6M)
Retained Earnings	(160.9M)	(249.1M)	(325.5M)	(383.8M)	(345.4M)	(328.1M)
Accounts Payable	3.1M	3.1M	1.1M	2.6M	2.3M	2.4M
Cash	198.1M	120.4M	44.7M	55.3M	63.6M	89.2M
Other Current Assets	4.5M	4.1M	3.4M	4.9M	5.7M	3.8M
Total Liab	36.2M	33.5M	24.1M	53.5M	61.5M	39.1M
Net Invested Capital	195.1M	115.5M	40.1M	17.6M	20.2M	19.2M
Total Current Assets	202.5M	124.5M	48.1M	60.2M	69.3M	93.0M
Net Working Capital	189.7M	103.4M	32.2M	33.0M	29.7M	53.7M
Short Term Debt	883K	7.6M	3.3M	1.2M	1.1M	1.0M

Today, most investors in Xilio Development Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Xilio Development's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Xilio Development growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0136

At this time, Xilio Development's Price Earnings To Growth Ratio is very stable compared to the past year.

Xilio Development February 10, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Xilio Development help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Xilio Development. We use our internally-developed statistical techniques to arrive at the intrinsic value of Xilio Development based on widely used predictive technical indicators. In general, we focus on analyzing Xilio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Xilio Development's daily price indicators and compare them against related drivers.

	Information Ratio	(0.21)
	Maximum Drawdown	15.41
	Value At Risk	(5.56)
	Potential Upside	4.17

When determining whether Xilio Development offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xilio Development's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xilio Development Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xilio Development Stock:

How To Invest In Xilio

Details

Is Xilio Stock a good investment?

Details

What is Xilio Development's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xilio Development. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Will Biotechnology sector continue expanding? Could Xilio diversify its offerings? Factors like these will boost the valuation of Xilio Development. Anticipated expansion of Xilio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xilio Development data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(0.61)

Revenue Per Share

0.614

Quarterly Revenue Growth

7.425

Return On Assets

(0.26)

Return On Equity

(9.08)

The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Xilio Development's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Xilio Development Financials

Xilio Development Balance Sheet Chart

Net Income

(55.04 Million)

Xilio Development Stock Summary

Xilio Development Key Financial Ratios

Xilio Development Key Balance Sheet Accounts

Xilio Development Key Income Statement Accounts

Xilio Development Key Cash Accounts

Xilio Financial Ratios Relationships

Xilio Development fundamental ratios Correlations

Xilio Development Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Xilio Development fundamental ratios Accounts

Price Earnings To Growth Ratio

0.0136

Xilio Development February 10, 2026 Opportunity Range

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Common Stock Shares Outstanding	- 0.98	Other Current Liab
Net Debt	- 0.98	Total Assets
Net Invested Capital	- 0.97	Net Debt